UniProtKB/Swiss-Prot P29033: Variant p.Gly160Ser

Gap junction beta-2 protein
Gene: GJB2
Feedback?

Variant information Variant position:

160 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Serine (S) at position 160 (G160S, p.Gly160Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs34988750 [ dbSNP | Ensembl ]

Sequence information Variant position:

160 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

226 The length of the canonical sequence.
Location on the sequence:

IFFRVIFEAAFMYVFYVMYD G FSMQRLVKCNAWPCPNTVDC The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDC

Gorilla                       IFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDC

Rhesus macaque                IFFRVVFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDC

Mouse                         IFFRVIFEAVFMYVFYIMYNGFFMQRLVKCNAWPCPNTVDC

Rat                           IFFRVIFEAVFMYVFYIMYNGFFMQRLVKCNAWPCPNTVDC

Bovine                        IFFRVIFEAAFMYVFYVMYDGFAMQRLVKCNAWPCPNTVDC

Sheep                         IFFRVIFEAAFMYVFYVMYDGFAMQRLVKCNAWPCPNTVDC

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 226	Gap junction beta-2 protein
Topological domain	157 – 189	Extracellular
Disulfide bond	53 – 180
Disulfide bond	60 – 174
Disulfide bond	64 – 169
Beta strand	159 – 162

Literature citations
Low frequency of deafness-associated GJB2 variants in Kenya and Sudan and novel GJB2 variants.
Gasmelseed N.M.A.; Schmidt M.; Magzoub M.M.A.; Macharia M.; Elmustafa O.M.; Ototo B.; Winkler E.; Ruge G.; Horstmann R.D.; Meyer C.G.;
Hum. Mutat. 23:206-207(2004)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT DFNB1A ILE-37; VARIANTS 46-ASP--GLN-48 DELINS GLU; HIS-127; ILE-153; SER-160 AND MET-167; Identification of mutations in the connexin 26 gene that cause autosomal recessive nonsyndromic hearing loss.
Scott D.A.; Kraft M.L.; Carmi R.; Ramesh A.; Elbedour K.; Yairi Y.; Srikumari Srisailapathy C.R.; Rosengren S.S.; Markham A.F.; Mueller R.F.; Lench N.J.; van Camp G.; Smith R.J.H.; Sheffield V.C.;
Hum. Mutat. 11:387-394(1998)
Cited for: VARIANTS LEU-83 AND SER-160; VARIANT DFNB1A THR-34;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.